Dose-Escalation Regimens for Incretin Mimetics in Type 2 Diabetes Are Associated With Tolerance for Nausea and Vomiting. | Synapse
March 1, 2026
Dose-Escalation Regimens for Incretin Mimetics in Type 2 Diabetes Are Associated With Tolerance for Nausea and Vomiting.
Key Points
The study aims to evaluate the effects of dose-escalation regimens on tolerance to nausea and vomiting in patients with type 2 diabetes receiving incretin mimetics.
Examined dose-escalation regimens for incretin mimetics
Assessed changes in nausea and vomiting tolerance
Correlated higher doses with therapeutic effectiveness
Optimized regimens resulted in greater tolerance for nausea and vomiting
Higher doses were associated with increased treatment effectiveness
Abstract
Taken together, optimised dose-escalation regimens may lead to greater tolerance for nausea and vomiting, which allows to use of higher doses, which are associated with greater therapeutic effectiveness.